Aaron Spector
Psychiatric/Mental Health · Marlton, NJNPI 1619077716
Payments from drug & device makers
Across 648 payments — averaging $154.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$54K
- AbbVie$33K
- E.r. Squibb & Sons, L.L.C.$6K
- Alkermes, Inc.$4K
- Sunovion Pharmaceuticals Inc.$707
- Bausch Health US, LLC$670
- plus $3K from 20 others
What the payments were for
- Consulting fees$4,2384%
- Speaking & faculty fees$83,98584%
- Travel & lodging$2,9893%
- Food & beverage$9,1379%
- Education$70%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 200 | $53,779 |
| AbbVie | 152 | $33,144 |
| E.r. Squibb & Sons, L.L.C. | 21 | $5,696 |
| Alkermes, Inc. | 32 | $3,658 |
| Sunovion Pharmaceuticals Inc. | 39 | $707 |
| Bausch Health US, LLC | 46 | $670 |
| Teva Pharmaceuticals USA, Inc. | 7 | $536 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 33 | $437 |
| Takeda Pharmaceuticals U.S.A., Inc. | 24 | $316 |
| Axsome Therapeutics, Inc. | 15 | $237 |
| Lundbeck LLC | 11 | $153 |
| Vanda Pharmaceuticals Inc. | 10 | $142 |
| Corium, LLC | 9 | $137 |
| Johnson & Johnson | 6 | $99 |
| Adlon Therapeutics L.p. | 6 | $85 |
| Supernus Pharmaceuticals, Inc. | 3 | $81 |
| Ironshore Pharmaceuticals Inc. | 5 | $71 |
| Eisai Inc. | 5 | $67 |
| Neurocrine Biosciences, Inc. | 4 | $61 |
| Idorsia Pharmaceuticals US Inc | 4 | $58 |
| Almatica Pharma LLC | 4 | $57 |
| Noven Therapeutics, LLC | 4 | $53 |
| Jazz Pharmaceuticals Inc. | 3 | $41 |
| Tris Pharma Inc | 2 | $31 |
| Avanir Pharmaceuticals, Inc. | 2 | $25 |
| Neos Therapeutics, LP | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$31,498
- REXULTI$30,579
- ABILIFY MAINTENA$20,016
- ARISTADA$12,060
- ABILIFY ASIMTUFII$10,547
- ARISTADA INITIO$3,015
- LYBALVI$1,600
- UZEDY$450
How this compares
$100,357 in reported general payments places this provider in the 95th percentile of 1,212 psychiatric/mental health providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FanaptIloperidone | 17 | $54,040 |
| RexultiBrexpiprazole | 36 | $52,116 |
| VraylarCariprazine Hcl | 18 | $31,300 |
| TrintellixVortioxetine Hydrobromide | 25 | $16,047 |
| VyvanseLisdexamfetamine Dimesylate | 13 | $5,437 |
| Vilazodone Hcl | 40 | $5,239 |
| Paliperidone ErPaliperidone | 22 | $5,084 |
| Clozapine | 11 | $4,318 |
| Duloxetine Hcl | 132 | $4,061 |
| Lisdexamfetamine Dimesylate | 13 | $3,614 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 33 | $3,214 |
| Divalproex Sodium ErDivalproex Sodium | 18 | $3,203 |
| Bupropion XlBupropion Hcl | 119 | $2,865 |
| Aripiprazole | 49 | $2,651 |
| Quetiapine Fumarate | 111 | $2,167 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Vanda Pharmaceuticals Inc.Fanapt | $142 | $54,04017 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $53,779 | $52,11636 claims |
| AbbVieVraylar | $33,144 | $31,30018 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $316 | $21,48438 claims |
| Almatica Pharma LLCSertraline Hcl | $57 | $51044 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,212 psychiatric/mental health providers in New Jersey.
Other psychiatric/mental health in Marlton
- Ubong UdofiaMarlton$407K
- Regina GarbarinoMarlton$12K
- Stella OkahMarlton$7K
- Anthony DimuraRed Bank$130K
- Amy PinsenNewton$111K
- Fiorella ParadisiSparta$84K
- Diane BurtBridgeton$81K
- Alta ManessHackensack$75K
- Laura LeahySewell$41K
- Linda WinfulMontclair$40K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.